NCT04706741View on ClinicalTrials.gov

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

August 25, 2022

Study Completion Date

November 14, 2022

Conditions
Uveitis
Interventions
DRUG

Izokibep

Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously

DRUG

Prednisone/Prednisolone

Background Corticosteroid

Trial Locations (4)

21740

Research Site, Hagerstown

75075

Research Site, Plano

90211

Research Site, Los Angeles

94303

Research Site, Palo Alto

All Listed Sponsors
lead

ACELYRIN Inc.

INDUSTRY

NCT04706741 - A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis | Biotech Hunter | Biotech Hunter